Rituximab cuts autoantibodies to insulin in study

08/18/2011 | HealthDay News

Rituximab treatment worked better than a placebo in suppressing autoantibodies to insulin in patients with new-onset type 1 diabetes, a study in Diabetes found. About 40% of rituximab-treated patients had no IAAs after a year, while no patient on the placebo had the same result, researchers said.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY